Treatment of Canine Leishmaniasis with Meglumine Antimoniate: A Clinical Study of Tolerability and Efficacy.
adverse effects
canine leishmaniasis
efficacy
meglumine antimoniate
Journal
Animals : an open access journal from MDPI
ISSN: 2076-2615
Titre abrégé: Animals (Basel)
Pays: Switzerland
ID NLM: 101635614
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
03
07
2024
revised:
27
07
2024
accepted:
29
07
2024
medline:
10
8
2024
pubmed:
10
8
2024
entrez:
10
8
2024
Statut:
epublish
Résumé
Antimoniate therapy, in association with allopurinol, is one of the first-line treatments of canine leishmaniasis (CanL). This study evaluates the potential adverse effects associated with aNm in the treatment of CanL through both a retrospective analysis and a long-term prospective study also aimed to investigate its efficacy. The retrospective study reviewed records of 87 dogs with CanL with at least one follow-up available during or at the end of therapy with aNm (Glucantime
Identifiants
pubmed: 39123770
pii: ani14152244
doi: 10.3390/ani14152244
pii:
doi:
Types de publication
Journal Article
Langues
eng